Correction to: European Journal of Human Genetics https://doi.org/10.1038/s41431-022-01243-2, published online 28 November 2022
Supplementary Table 3 contained two incorrectly predicted phenotypes based on the described genetic variant combinations (rs number variants). Supplementary Table 3 has been simplified and updated accordingly.
This table includes UGT1A1 alleles with a minor allele frequency ≥ 1% in either the White, African or Asian population.
According to the allele definition table of PharmGKB, there is no allele including two of the polymorphisms (https://www.pharmgkb.org/haplotype/PA166115865, accessed on 16 December 2022). This suggests that alleles including two or more of these polymorphisms are either very rare or non-existent. For this reason, genotypes with 3 or 4 polymorphisms were not included in the translation table. In addition, in compound heterozygotes, both polymorphisms were considered to be on different alleles.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Hulshof, E.C., Deenen, M.J., Nijenhuis, M. et al. Correction: Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between UGT1A1 and irinotecan. Eur J Hum Genet 31, 1088–1089 (2023). https://doi.org/10.1038/s41431-023-01315-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41431-023-01315-x
